$CBIS Up to date company activities and other important

New Post Public Reply Private Reply Replies (0) Message Board

Feb 5, 2014 at 3:02 PM

$CBIS Up to date company activities and other important information about $CBIS

$CBIS

DD Notes ~ http://www.ddnotesmaker.com/CBIS

##### recent news/filings ~ source: finance.yahoo.com

Wed, 05 Feb 2014 17:48:00 GMT ~ Cannabis Science (CBIS) Collaborates with Patients Out of Time, Inc., a Global Patient Advocacy Organization Dedicated to Educating Health Professionals and the Public about Therapeutic Cannabis
- COLORADO SPRINGS, Colo., Feb. 5, 2014 /PRNewswire/ -- (NASD OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, provides development consultation and financial support to Patients Out of Time, Inc., the premiere non-profit organization devoted to helping educate the public and healthcare professionals about the safety and effectiveness of medical cannabis. Cannabis Science is pleased to facilitate the critical work of this unique non-profit organization's ongoing conferences, events, workshops and global distribution of leading edge educational content and online resources. CBIS's support includes supporting Patients Out of Time's marquee conference in Portland, Oregon in May 2014, entitled "The Eighth National Clinical Conference on Cannabis Therapeutics", and future conferences, helping to expand the organization's conferences from biennial to annual, for which participants or learners may earn ACCME (fully recognized continuing education) credits.
read full: http://finance.yahoo.com/news/cannabis-scienc...00369.html
*********************************************************

Tue, 04 Feb 2014 13:52:00 GMT ~ Cannabis Science (CBIS) Applauds U.S. Congress on Moving to Legalize Hemp Cultivation and Research; Calls Today for Final Senate Passage of Farm Bill and President's Signature into Law
- COLORADO SPRINGS, Colo., Feb. 4, 2014 /PRNewswire/ -- Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, is pleased that the U.S. Congress and President Obama appear positioned to approve the first federal law to legalize hemp cultivation and advanced research on a federal level, creating unprecedented opportunities for the Company to pursue patient-based pharmaceutical solutions for patients. Last week the U.S. House of Representatives approved the "farm bill" that contains a provision for certain cultivation of industrial hemp for research in a number of U.S. states. The Senate is expected to approve the measure as soon as today, and President Obama has declared that he will sign the bill into law, changing the legal landscape for the entire hemp industry. "As hemp and cannabis both come from the same plant, federal movement on liberalization of hemp cultivation and research will positively impact Cannabis Science's opportunities for pharmaceutical research and development of cannabis and cannabinoid-based pharmaceutical products for patients. The House has approved the bill, and the Senate is expected vote in favor of it today or tomorrow, with near certain approval from the President. The Company is formulating its strategy for this regulatory opening to more quickly bring pharmaceutical products to market for the benefit of patients in need," said Chad S. Johnson, Chief Operating Officer and General Counsel of Endocan Corporation.
read full: http://finance.yahoo.com/news/cannabis-scienc...00205.html
*********************************************************

Mon, 03 Feb 2014 23:39:16 GMT ~ 8:28 am Cannabis Science provides growth guidance for its gross profit sharing exclusive and non-exclusive agreement in select markets with MDS, a subsidiary of Medbox (MDBX); CBIS sees Canada as flagship
- 8:28 am Cannabis Science provides growth guidance for its gross profit sharing exclusive and non-exclusive agreement in select markets with MDS, a subsidiary of Medbox (MDBX); CBIS sees Canada as flagship market launch
read full: http://finance.yahoo.com/news/inplay-briefing....html#cbis
*********************************************************

Mon, 03 Feb 2014 13:26:00 GMT ~ CBIS Provides Growth Guidance on its Medicine Dispensing Systems (MDS) Exclusive & Non-Exclusive Agreements
- COLORADO SPRINGS, Colo., Feb. 3, 2014 /PRNewswire/ -- (NASDAQ OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, provides ...
read full: http://finance.yahoo.com/news/cbis-provides-g...00614.html
*********************************************************

Wed, 29 Jan 2014 17:55:00 GMT ~ Cannabis Science (CBIS) Government Affairs Representative Lobbys' with the U.S. House of Representatives' Cannabis Caucus for President Obama to Join Congressional Cannabis Caucus in Ending Federal Restrictions on Cannabinoid Research
- COLORADO SPRINGS, Colo., Jan. 29, 2014 /PRNewswire/ -- (NASDAQ OTC: CBIS) After President Obama's State of the Union Address this week, Cannabis Science is leading the private sector effort to take cannabis-derived drugs to market. The company's government relations team lead, Rick Blake, is working with the U.S. House of Representatives' Cannabis Caucus to ensure that the President signs an Executive Order to decriminalize cannabis research. This is one of the bipartisan initiatives of the Members of the Cannabis Caucus being facilitated by Cannabis Science. In contrast to many other countries, the regulatory landscape of the United States creates unreasonable restrictions on the ability of scientists and physicians to explore promising patient-driven research involving cannabis and cannabinoids. "Thousands of patients are awaiting the President's action to set cannabis research free," said Dorothy Bray, Ph.D., Director and CEO of Cannabis Science, Inc., one of the leading supporters of scientific cannabis drug development in the private sector. We applaud those congressional members in Colorado, California, Oregon, New York, Massachusetts and many other jurisdictions in the United States who have determined to take forward U.S. cannabis drug research." Dr. Bray and others on the CBIS team support critical legislation for the use of cannabis in the treatment of multiple illnesses including cancer.
read full: http://finance.yahoo.com/news/cannabis-scienc...00858.html
*********************************************************

##### chart ~ source: stockcharts.com

stockcharts.com/c-sc/sc?s=CBIS&p=D&b=5&g=0&id=p95448242713

##### chart ~ source: eoddata.com

http://chart.eoddata.com/?e=OTCBB&s=CBIS&...D&b=BB

##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CBIS/company-info
Ticker: $CBIS
OTC Market Place: OTCQB
CIK code: 0001024626
Company name: Cannabis Science, Inc.
Company website: http://www.cannabisscience.com
Incorporated In: NV, USA

##### extra dd links

Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/CBIS/filings
Latest financials: http://www.otcmarkets.com/stock/CBIS/financials
Latest news: http://www.otcmarkets.com/stock/CBIS/news - http://finance.yahoo.com/q/h?s=CBIS+Headlines

Major holdings: http://data.cnbc.com/quotes/CBIS/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=CBIS+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/CBIS.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=CBIS

RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search

DTCC: http://search2.dtcc.com/?q=Cannabis+Science%2...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...nce%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.cannabisscience.com
Alexa: http://www.alexa.com/siteinfo/http://www.cann...ience.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.cannabisscience.com

http://www.pennystocktweets.com/stocks/profile/CBIS

##### last known share structure ~ source: otcmarkets.com

Market Value: $170,460,423 a/o Feb 04, 2014
Shares Outstanding: 761,323,906 a/o Nov 18, 2013
Float: 24,000,000 a/o Jun 17, 2010
Authorized Shares: 250,000,000 a/o Jun 17, 2010
Par Value: 0.001

##### business description ~ source: otcmarkets.com

Research & Development of medical cannabis compounds

DD Notes ~ http://www.ddnotesmaker.com/CBIS

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Aluminum Design Fumble: Geometry Over Wall Thickness

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Axon Body 5: A Leap Forward in AI for Public Safety

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Swanson Nexus Pro Launch: Boost for Dietitians

By Lucas Young Updated Oct 24, 2026 Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Survivors Secure $800M Settlement with NY Archdiocese

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...